Introduction: QT has a long history of heart rate (HR) correction but limited investigations have been undertaken to assess the impact of cardiovascular parameters on left ventricular (LV) contractility in drug safety testing. Cardiac contractility is affected by preload (Cyon-Frank-Starling law), afterload (Anrep effect) and HR (Bowditch effect). We evaluated multi-parameter correction methods to help with dP/dt max interpretation. Methodology: Modeling was undertaken using data from dogs in single or double 4 × 4 Latin square studies. Correction models (16 fitting formulas × 2 modeling approaches (universal and individualized) × 2 correction approaches (linear or proportional)) were evaluated. 3D/2D cloud analysis of the beat-to-beat data for the control, pimobendan, and either itraconazole or atenolol groups were used to evaluate correlations between parameters and derive an optimal correction method. Results: Cardiac contractility (i.e., dP/dt max ) was best correlated to HR and systolic LV pressure with a correlation coefficient of 0.8. In decreasing order, dP/dt min , mean arterial blood pressure (BP), systolic BP, diastolic BP, arterial pulse pressure and LV end diastolic pressure (LVEDP) showed a reduced correlation to dP/ dt max . Subject-specific models improved the correction by up to 14% when compared to universal correction models. The non-linear correction model was superior to the linear model. Discussion: Results suggest that the optimal correction formula for dP/dt max would be subject-specific, non-linear and would include HR and LV systolic pressure. Correcting contractility for HR and systolic LV pressure may enhance data interpretation in non-clinical drug safety assessments. Similar correction methods could be evaluated for other species used in safety pharmacology.
Introduction
While the QT interval has a long history associated with multiple attempts to correct for changes due to heart rate (HR) (Bazett, 1920; Fridericia, 2003; Spence, Soper, Hoe, & Coleman, 1998; Van de Water, Verheyen, Xhonneux, & Reneman, 1989) , limited investigation has been undertaken to assess the impact of changes in cardiovascular parameters on left ventricular (LV) contractility. The inclusion of contractility parameters in the standard cardiovascular evaluation of a new chemical entity (NCE) has become routine (Markert et al., 2012) for studies that traditionally employ the use of telemetry techniques to monitor drug-associated effects on blood pressure (BP), HR and the electrocardiogram (ECG) (Markert et al., 2012) . However, no consensus exists regarding the degree of change to the measures of contractility necessary before there is concern regarding the safety profile of the NCE. An HESI-sponsored consortium assessed methodologies most commonly used to evaluate drug effects on contractility using drugs with positive and negative effects on myocardial contractility (Guth et al., 2015) . Cardiac contractility is influenced by multiple cardiac factors, such as the preload (as defined according to the Cyon-FrankStarling law), afterload (or Anrep effect) and heart rate (or Bowditch effect) -all of which coordinate and modulate the force of contraction and cardiac stroke volume (Cingolani, Perez, Cingolani, & Ennis, 2013; Ker, 2009; Moss & Fitzsimons, 2002) . However, cardiac contractility can also be greatly influenced by pharmacological agents that act either directly or indirectly on heart function as either positive or negative inotropes. For example, the antifungal drug itraconazole (a triazole) has been shown to cause significant reductions in cardiac contractility but no distinct mechanism of action has been defined for this effect (Qu et al., 2013) . Similarly, the oncology drug, doxorubicin (an anthracycline), is known to induce severe depression of left ventricular systolic pressure (LV Sys), maximum rate of rise of left ventricular pressure (dP/ dt max ) (an index of cardiac contractility), cardiac output and stroke work (Bátkai & Pacher, 2009) .
Analysis of cardiac contractility parameters commonly rely upon statistical methods that evaluate changes by generating P-values. However, use of magnitudes of change in a specific parameter based solely upon P-values gives no indication of the clinical importance of an observed effect (Whitley & Ball, 2002) and it has been suggested that the common application of α = 0.05 may entail inference limitations (Curtis et al., 2015) . Cloud analysis can be a useful technique for cardiac contractility data evaluation and interpretation, especially the application of 2D cloud analysis which can be used to represent beatby-beat data via marginal distribution curves which describe data density (Accardi et al., 2016) and detect outlier data (Buchanan et al., 2016 ). An extension of this involves 3D cloud analysis which can enhance the utility of the cloud analysis technique by comparing the relationships between three parameters (e.g., dP/dt max , HR, and the LV Sys) which can be used to generate a qualitative 3D representation that can help visualize drug-induced effects. Chronotropic (direct or indirect) effects are amongst the most common in drug safety testing and non-clinical assay sensitivity is essential. We aimed to evaluate this novel methodology to characterize the pharmacodynamic response of cardiac contractility parameters measured in standard Beagle dogs instrumented with implantable telemetry systems administered drugs known to increase (pimobendan) or decrease (itraconazole and atenolol) the inotropic state of the heart (Guth et al., 2015) . In doing so, we provide a potentially more sensitive approach to detect drug induced inotropic effects using a non-linear formula to correct dP/dt max in order to assess drug-mediated effects on cardiac contractile function for use in non-clinical drug safety assessments.
Materials and methods

Test facility and experimental animals
The data used within this investigation were obtained from the HESI-sponsored Consortium, as outlined previously (Guth et al., 2015) . The in-life phase of the study, from which the data were collected, was subjected to local guidelines in terms of the vivarium conditions, study conduct and animal use approval procedures. Male Beagle dogs were surgically instrumented with either the DSI Physiotel™ Digital L21 or D70-PCTP telemetry system (DSI, St. Paul, MN, USA) to monitor SABP, LV pressure, the electrocardiogram (EKG), body temperature and activity as previously described (Guth et al., 2015) . After an appropriate recovery period following surgery or washout period after receiving a drug, animals were subjected to a standard clinical pathology examination to evaluate their health status according to local procedures.
Test drugs and study design
Animal placement and dosing regimens were based and analyzed on a double 4 × 4 Latin square design (n = 8) for the pimobendan and itraconzole data and a single 4 × 4 Latin square design (n = 4) for the atenolol. The dosing regimen was designed to ensure that all dose levels were represented on each dosing day and no animal received a dosage more than once. A double 4 × 4 Latin square, a combination of two identical 4 × 4 Latin squares, results in a study design consisting of 4 rows and 8 columns. An appropriate washout period (minimum of 72 h between treatment days which represented at least 6 half-lives for the drugs that were used) was observed. Food was withdrawn approximately 2 h before dosing in the morning and reintroduced in the afternoon, which was well after the anticipated time of maximal plasma concentration (T max ) of the tested drug.
Three drugs were reported within this investigation, each of which possesses a known positive or negative inotropic effect when given to humans in the clinical setting. All drugs were administered orally. Pimobendan and itraconazole were administered to the same animals (n = 8) after appropriate washout periods. Atenolol was administered to three independent animals (n = 3), which had not previously received pimobendan or itraconazole. Pimobendan is recognized as a calcium (Ca 2 + ) sensitizer and a selective inhibitor of phosphodiesterase-3 with positive inotropic and vasodilator effects, and was formulated using the PCCA Fixed Oil Suspension Vehicle™ to dose levels of 0.1, 0.3 and 1 mg/kg. Itraconazole, a negative inotropic agent, was formulated using 0.5% (w/w) methocel E50 in water containing 0.01% (w/w) polysorbate 80 and 10 mM phosphate buffer (pH 6.80-7.20 ) to dose levels of 3, 10, and 30 mg/kg. Atenolol is a selective beta-1 receptor antagonist, and as such, it decreases HR and workload. It was formulated using deionized water to dose levels of 0.3, 1 and 3 mg/kg. Each drug condition was tested with their respective vehicles (Table 1) .
Data collection and analysis
LV pressure, BP and ECG signals were continuously acquired from at least 1 h prior to dosing through 24 h post-dose on each study day. Sampling rates were ≥ 500 Hz for LV pressure and ECG, ≥ 250 Hz for BP signals. A variety of derived parameters were calculated by the Ponemah (DSI, St. Paul, MN, USA) data analysis software which included: HR, diastolic, systolic and mean (aortic) BP, pulse pressure, end-diastolic and peak systolic LVP, dP/dt max , dP/dt min , dP/dt 40 , Tau and the QA interval (Guth et al., 2015) . Although a large number of parameters were available, this manuscript is limited to cardiac function and to hemodynamic parameters that are directly or indirectly relevant to the evaluation of cardiac contractility such as LV Sys, LV dP/ dt max , and HR. Data were analyzed and presented using Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). 2D/3D cloud analysis was conducted using beat-to-beat contractility data and prepared using the Origin 2016 software (OriginLab, Northampton, MA, USA) for qualitative data interpretation. Table 1 Drugs tested in conscious telemetered dogs for effects on left ventricular contractility.
Drug
Method of administration Doses (mg/kg) Formulation/vehicle 2.3.1. Preprocessing For each recording, the acquisition system output three-time series at each heartbeat: HR or RR interval, the LV Sys and the contractility quantified by the maximal derivative of the LV pressure over time (dP/ dt max ) were extracted. A series of exclusion criteria were established prior to data analysis and included values beyond those considered physiologically relevant. The standard ranges of values included in the data analysis were 40-400 bpm for HR, 90 to 320 mm Hg for LV Sys and 2000 to 20,000 mm Hg/s for dP/dt max . (Gauvin, Tilley, Smith, & Baird 2006) . A median filter (i.e., a filter that does not distort fine signal detail while effectively suppressing noise or outliers) of order 5 was used to further remove outliers. Then, high-frequency noise was eliminated by applying a moving average filter (i.e., a simple Low Pass FIR (Finite Impulse Response) filter that is commonly used for smoothing an array of sampled data/signal) of the order 10. HR was converted to RR intervals, filtered, and then converted back to HR to ensure data consistency. Finally, to create regularly sampled signals and reduce data size, continuously acquired values were collapsed into 10 s means for analysis.
Parameter estimation
The dP/dt max was predicted based on HR and LV Sys using the formulas presented below and the correction formula with different data bin intervals are in Table 2 .
Parameter estimation was done in Matlab (The Mathworks Inc., Natick, MA, USA). Matlab (matrix laboratory) is a multi-paradigm computer program that allows for development and application of data analysis equations to data sets using a Matlab scripting computer programming language. For the additive family of equations (formulas 1 to 10 in Table 3 ), optimization was based on three principles: (1) the mean of the residual must be zero so the prediction is unbiased: mean (epsilon) = 0; (2) the residual must be uncorrelated to the variables: cov(epsilon, HR) = cov(epsilon, LV Sys) = 0; and (3) the root mean square error (RMSE = [mean(epsilon 
). The minimum of that cost function was computed using the Matlab routine "fminsearch" (multidimensional minimization) starting from the initial estimate (b = 1, d = 1). When simpler formulas were used (e.g., formula 5 where c = 0), one equation was dropped (which implies: a = cov(dP/dt max , HR)/cov(HR b , HR)), and the cost function had only one parameter (b) that was optimized using the Matlab routine "fminbnd" (one-dimensional minimization) starting from the interval [0.1, 8] . In the linear cases (b = d = 1), no minimization was needed since the covariance criterion was sufficient to determine the parameters.
The multiplicative family of equations (formulas 11 to 16 in Table 3 ) extends the Markert et al. (2012) and the Spence et al. (1998) approaches. Parameters were estimated by linear regression of the logarithm (e.g., in formula 14, log(dP/dt max ) = log(a) + b log(HR) + c log(Sys) + d HR + e Sys). When polynomials of degree 4 or more were used in the exponential (generalization of formula 16 in Table 3 ), the least square system was sometimes ill-conditioned, so we only considered degrees < 4. When parameter estimation was performed separately on the data of each dog in control, the resulting model was said to be individualized. When the data from all dogs in control were pooled together for parameter estimation, the resulting model was called universal.
Correction formulas
Once the fitting function f(HR, LV Sys) is determined, there are two ways to derive a (dP/dt max ) time series corrected for HR and/or LV Sys:
The linear correction formula: (dP/dt max ) corr = dP/dt max − f(HR, LV Sys) + f(HR ref , LV Sys ref Provided that the fitting function takes into account both HR and LV Sys, application of a linear correction ensures that cov((+ dP/dt) corr , HR) = cov((dP/dt max ) corr , LV Sys) = 0, since the sum of the first two terms is equal to epsilon.
In total, there were 64 correction models evaluated: 16 fitting formulas × 2 modeling approaches (universal and individualized) × 2 correction approaches (linear or proportional). The accuracy of correction formula can be assessed by computing the standard deviation of (dP/dt max ) corr , which measures its stability over time in controls. Another measure used in determining accuracy is the residual correlation coefficient between (dP/dt max ) corr and HR or LV Sys. Fig. 2 . Performance of the correction formulas grouped as 'linear vs. proportional' correction and 'universal vs individualized' formulas. Right panel of each subplot: Root mean square (mean ± standard deviation for 14 animals) of the corrected (dP/dt max ) corr divided by its average value (3800 mmHg/s), for all the correction models with 2 to 5 adjusted parameters, with individualized or universal fitting and with a linear or proportional correction approach. Left panels: sum of the absolute value of the correlation coefficients (CC) between (dP/ dt max ) corr and HR and Sys LVP. The contribution of HR and Sys LVP to the sum is shown in different shades of gray.
Results
The different variables included in the correction formula were identified from the correlation coefficient between dP/dt max and the other variables. dP/dt max was best correlated to both HR and systolic LV pressure with a correlation coefficient of 0.8. Correlations between dP/ dt max and other variables were < 0.7, except for dP/dt 40 which provides an estimate of the same physiological parameter (Fig. 1) . HR and systolic LV pressure had a correlation of 0.69. These correlations motivated our choice to correct dP/dt max based on HR and systolic LVP. Another important argument is the ability to extract a measure of contractility that is independent of HR and LV Sys in such a way that the effects of a drug on contractility can be ideally studied independently from effects on HR and LV pressure.
A total of 64 formulas were investigated in order to correct dP/dt max for HR and LV Sys, and were compared in terms of the root mean square of the residual and the residual correlation with HR and LV Sys (Fig. 2) . Individualized correction formula was superior by up to 14% and, more importantly, the residual correlation between the corrected dP/dt max and HR and LV Sys were considerably reduced, notably in the best performing models. Despite a slightly larger residual correlation, the proportional corrections had smaller root mean square residuals by up to 20% as compared to the linear correction formula. Therefore, individualized corrections using the proportional formula were preferred. Amongst the different mathematical formulations, the Markert formula was the best performing one-variable formula (formula 11 in Table 3 ) examined and the generalized Markert formula (formula 14 in Table 3 ) was the best correction formula overall. Adding additional parameters in the exponent (formulas 15 and 16 in Table 3 ) did not improve the performance sufficiently to justify the estimation of multiple additional parameters. Formula 10, on the other hand, requires non-linear parameter estimation which complicates the process without an improvement in its performance. This analysis supports the use of the two-variable, five-parameter, individualized, generalized Markert formula with proportional correction. The corrected dP/dt max later presented in this article will refer to that correction.
Power analysis was used for a theoretical estimation of the impact of the reduction in dP/dt max variability resulting from the correction. A simulated sample size was selected (1 sample every 10 s for 10 min to compare the dP/dt max ) and the alpha significance level threshold was set to 5% (Fig. 3) . Assuming a target power of 0.8, the minimum detectable difference between the Markert model (correcting for HR only) and the two variables correction model (correcting for HR and LV Sys) decreases from 4.25% to 3.5% (Fig. 3) .
As expected, uncorrected dP/dt max data were more variable than corrected dP/dt max ( Fig. 4A ) with greater variations occurring during day time. Similarly, beat-to-beat uncorrected dP/dt max data (Fig. 4B) were more variable than corrected data (Fig. 4C) . Beyond a decrease in variability, the individual correction also attenuated circadian cycle fluctuations as shown between 00:26 and 5:06 when the uncorrected dP/dt max decreased between 2900 and 3700 mm Hg/s while the corrected values remained between 3800 and 4900 mm Hg/s. 3D cloud graphs can be used to illustrate the impact of HR and LV Sys correction on dP/dt max (Fig. 5A) .
Itraconazole
Application of the correction formula to dP/dt max can even be beneficial with a single animal. The inotropic effects of itraconazole can be easily identified on a 3D graph (Fig. 5B) as the control treatment is associated with values between 3781 and 5159 mm Hg/s and itraco- Fig. 3 . Power analysis showing minimal detectable differences for the corrected dP/ dt max . The blue curve represents the Markert model (i.e., a correction for HR) and the red curve represents the combined correction model (i.e., correction for HR and LV Sys). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 4. A) A 24-h monitoring period for corrected and uncorrected dP/dt max from one representative animal during the control period illustrating the lower range of variations with the corrected data. A period with lower variability is noted during the night time (i.e., 00:26 to 05:06). Uncorrected (B) and corrected (C) beat-to-beat dP/dt max data over a 24 h period in a control animal illustrating the reduction in variability with corrected data. nazole (30 mg/kg) resulted in values from 2462 to 3917 mm Hg. Itraconazole (n = 8) yielded the expected negative inotropic effects at mid and high dose levels tested (Fig. 6A ). 3D graphs of the 24 h period (Fig. 6B) illustrate the shift in dP/dt max with treatment. When a 3D plot focused on T max is used ( Fig. 6C and D) , the negative inotropic effect of itraconazole can be clearly identified as the confidence ellipses are distinct from control treatment.
Pimobendan
Pimobendan (n = 8) also induced the expected positive inotropic effects at mid and high dose levels tested (Fig. 7A) . The low dose (0.1 mg/kg) showed no difference compared to the control data (between − 10.37% and + 10.37%), but the mid (0.3 mg/kg) and high dose (1.0 mg/kg) showed clear positive inotropic effects as illustrated using 3D graphs over a 24 h period (Fig. 7B) . A 3D graph focused on T max (Fig. 8C ) allowed for clear identification of the positive inotrope effects and the corrected dP/dt max (Fig. 7D ) appeared to improve the display of dose-dependent effects.
Atenolol
Atenolol (n = 3) was associated the expected negative inotropic effects at all dose levels tested (Fig. 8A) . The low dose (0.3 mg/kg), mid dose (1.0 mg/kg) and high dose (3.0 mg/kg) all showed dose-dependent negative inotropic effects. The 24-h 3D graph for uncorrected dP/ dt max did not allow for a clear identification of the drug effect; however, the 3D graph focused on T max allowed for identification of negative inotropic effects with uncorrected and corrected dP/dt max ( Fig. 8C and  D) . Interestingly, the 3D graphs uniquely illustrated that changes in dP/ dt max were closely correlated with changes in HR as the ellipses of the confidence intervals overlapped in the range of lower HR but the ellipses are clearly distinct at higher HR.
Discussion
Cardiac contractility is a major consideration in drug development but also in clinical cardiology with important patient implications from interactions between the two fields. Heart failure is a complex pathology involving structural deterioration of cardiac tissues with ventricular chamber dilation resulting in ventricular wall thinning. Often associated with increased peripheral vascular resistance and dysregulated fluid homeostasis, heart failure is a continuum characterized by progressive functional deficits (Dorn & Molkentin, 2004) in which patients have limited cardiac reserve. Canine heart failure models lack the normal positive correlation between HR and dP/dt max where an increase in HR is not associated with increased contractility (Asanoi et al., 1996) . While this relationship is altered in canine heart failure, dogs that are used for non-clinical drug safety testing are healthy with normal cardiac parameter correlation. Given the high prevalence of cardiac disease, increased susceptibility to drug-induced adverse cardiac effects is a common feature of the clinical population. From nonclinical to clinical studies, drug attrition due to cardiotoxicity is a major concern across a wide range of indications (Ferri et al., 2013) . In this context, the sensitivity of drug safety testing models to identify inotropic effects is recognized as a critical success factor to manage drug development efforts. Safety pharmacology has spent considerable efforts to enhance sensitivity and predictivity of methods to assess drug effects on ventricular repolarization (Guth et al., 2009; Vargas et al., 2015) . Safety pharmacologists have been tasked by the clinical community to develop models to identify clinically relevant cardiac changes during the assessment of an NCE (Bass et al., 2011) . To achieve this goal, refining data analysis is a potential avenue which was extensively explored for QT prolongation assessments (Authier, Pugsley, Troncy, & Curtis, 2010; Darpo et al., 2011; Garnett et al., 2012; Vicente et al., 2015) . Cardiac contractility data is rich with continuous multi-parameter monitoring used in most non-clinical drug safety testing studies (Accardi et al., 2016; McKee, Daller, Baumgartner, & Pettinger, 2014; Segreti, Polakowski, Blomme, & King, 2016) . The rate dependence of contractility parameters have been previously considered in order to identify inotropic effects independent from chronotropic changes (Markert et al., 2012) . Drug-induced chronotropic and positive/negative pressor effects are common in non-clinical cardiovascular safety studies and correcting for indirect effects could enable a more robust evaluation of contractility biomarkers. A drug induced decrease in dP/dt + can be indicative of a safety Fig. 5 . A) A 3D cloud graph of uncorrected dP/dt max (red) compared to the corrected dP/dt max (green) over a 24 h period. Data are 10 min averages obtained from a representative animal during the control period. B) A 3D cloud graph of corrected dP/dt max after itraconazole (30 mg/kg) (red) compared to corrected dP/dt max after control (green) over a 24 h period (10 min averages; 144 points). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) risk and a correction method that factors indirect effects on this parameter driven by HR and/or BP may help the safety pharmacologist determine the origin and importance of the change in the slope of the isovolumetric contraction. Drug-induced changes in HR are frequent in drug development and a multi-parameter correction method can be used to differentiate true inotropic effects from secondary changes in contractility due to alteration in HR or BP. This approach may be particularly important when severe HR or BP effects are noted for patient populations with higher risks for cardiac (e.g. cardiac diseases or oncology patients receiving chemotherapies).
3D cloud analysis is seldom used in the analysis of data derived from the conduct of safety pharmacology studies but has been widely applied to various other scientific disciplines including geomorphology, stratigraphy, tectonics, and mining to name a few (Abellan, Derron, & Jaboyedoff, 2016) primarily for such analysis to provide enhanced spatial representation. Beat-to-beat data presentation has previously been applied to ECG parameters to assess the dynamics of QT-RR and QT-TQ interval relationships through quantification of heterogeneity, hysteresis and restitution. Fossa's strategies highlight the importance of graphic representation in cardiac data analysis (Fossa & Zhou, 2010 ). In the current study, we explored the application of 2D/3D cloud analysis to safety pharmacology data focusing on cardiac contractility relationships. Primarily the relationship between dP/dt max to HR and systolic pressure was investigated by using a correction to discern inotropic effects from chronotropic and/or pressor effects. The 3D graph focused on the T max determined for the drugs administered and allowed for visualization of drug effect on contractility and the interaction with HR and LV Sys. Overall, a 24 h 3D graph appeared useful to screen for drug effects over the entire monitoring period as previous discussed when super-intervals were introduced (Sivarajah et al., 2010) . Cloud analysis was also reported to be useful to detect outlier data (Buchanan et al., 2016) which can be visualized outside the cloud margins and then excluded from interpretation (if artefactual).
Results from the current data analysis suggest that the optimal correction formula for dP/dt max that accounts for changes in HR and LV Sys in a standard safety pharmacology study would be a subject-specific (yielding a 14% improvement over a universal correction factor), nonlinear correction equation. These subject specific correction formulas follow a trend of multi-parametric correction methods as noted for QT interval. A method that applies the Van de Water ( Van de Water et al., 1989) formula combined with the Van der Linde formula (van der Linde, Van Deuren, Teisman, Towart, & Gallacher, 2008) to correct for body temperature was recently suggested to further improve analysis of Table 4 . Larger symbols represent the mean ± SE within each super-interval. B) A 3D cloud analysis of uncorrected dP/dt max for different itraconazole dose levels (control (red), low (green), mid (blue), high (teal)), with their respective confidence ellipse (95%) over a 24 h period using 10 min data averages (n = 8). (C) A 3D cloud graph of uncorrected dP/dt max and (D) corrected dP/dt max at T max (2 −3h) after itraconazole treatment (control (red), low (green), mid (blue), high (teal)), with their respective confidence ellipse (95%) using 10-min averages (n = 8 animals). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
QT data obtained in conscious dogs with implanted telemetry systems (El Amrani, El Amrani-Callens, Loriot, Singh, & Forster, 2016) . Individual QT correction methods were reported to significantly improve the ability to dissociate direct effects of drugs on the QT interval from HR changes in dogs over universal correction methods (Spence et al., 1998) . The individual correction formula variables that are obtained from 10 min mean data and beat-to-beat data indicate that this correction formula is specific to the data bin interval that was used (See Table 2 ). Also, a note of caution should be made with regard to the correction formula as it should not be extrapolated much beyond the data used for the fit derivation as the model may not accurately predict extrapolation. The individual correction formula with a proportional correction has been used where + dP/dt = a × HR b × Sys c × exp (d × HR + e × Sys) and gives nearly similar result as the formula + dP/dt = a × HR b + c × Sys d + e, which generalizes the Markert formula (Markert et al., 2012) and can be easily estimated using simple data analysis tools such as Microsoft Excel which may be advantageous to the safety pharmacologist. It remains that each laboratory should confirm that the proposed individual correction formula is the most effective methodology to correct for physiological changes in dP/dt + related to HR and systolic pressure changes. Circadian rhythms may also influence the progression of a variety of diseases as well as effectiveness and toxicity of drugs (Chan et al., 2012) . The circadian cycle modulates cardiovascular parameters in all species (Malpas & Purdie, 1990; Wang et al., 1999) .Within this study, circadian changes were observed amongst all cardiovascular parameters, as expected. The HR-dependent parameter, the QT interval, was also shown to present a shift in the QT-RR relationship with the circadian cycle (Soloviev, Hamlin, Barrett, Chengelis, & Schaefer, 2006) emphasizing the importance to consider and factor this phenomenon into any 24 h data set analysis. The kinetics of drug-induced dP/dt max effects often extend across day and into the night time periods, depending upon the half-life of the NCE and pharmacological activity of any major metabolites. The dP/dt max correction method proposed herein significantly attenuates circadian changes that correlate with significant BP and HR fluctuations and may facilitate a comparison of data across periods (i.e., day vs. night). Itraconazole (Sporanox) is an approved antifungal drug with an FDA blackbox warning regarding a risk for development of ventricular dysfunction or asymptomatic decreases in left ventricular ejection fraction that could result in development of congestive heart failure (Hauben & Hung, 2013) . The exact mechanism by which itraconazole exerts negative inotropic effects remains uncertain (Qu et al., 2013 ) but a direct effect on cardiomyoctes is potentially involved. The 3D graph Table 4 . Larger symbols represent the mean ± SE within each super-interval. B) A 3D cloud graph of uncorrected dP/dt max after pimobendan at different doses (control (red), low (green), mid (blue), high (teal)) with their respective confidence ellipse (95%) over a 24 h period using 10 min data averages (n = 8). (C) A 3D cloud graph of uncorrected dP/dt max and (D) corrected dP/dt max at T max (3-5 h) after pimobendan treatment (control (red), low (green), mid (blue), high (teal)), with their respective confidence ellipse (95%) using 10-min averages (n = 8 animals). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) of itraconazole effects at T max of the drug in this study suggests that a relatively uniform decrease in contractility occurs across of range of HR values. Pimobendan is a non-digitalis inotropic agent that increases the sensitivity of cardiac myofilament contractile activity to Ca 2 + (Fujino, Sperelakis, & Solaro, 1988; Pollesello, Papp, & Papp, 2016) . In a manner similar to that observed for itraconazole, the positive inotrope effects of pimobendan appeared similar across a range of HR values. Atenolol, a β1-selective adrenergic receptor blocker, decreased HR and also reduced cardiac contractility. While changes in corrected dP/dt max were similar at varying HR values in the dogs after itraconazole and pimobendan administration, atenolol was associated with a unique profile characterized by more pronounced negative inotropic effects at higher HR. This was likely related to the mechanism of action of a β1-selective blocker which requires catecholamine (typically associated with higher HR) to provide its full pharmacological effect. The distinct profiles observed with the three agents evaluated in the current study highlight potential benefits of 3D data representation which allows visualization of complex parameter correlation ("signature") that may not be evident with conventional 2D representations. While rate and pressure corrected dP/dt max is proposed to improve data analysis of the contractility assessment in a safety pharmacology study when using this parameter to assess drug effects, it remains that dP/dt max has intrinsic limitations to its application to drug safety assessments. As is widely accepted within the scientific community, the use of LVP-derived indices, such as dP/dt max , may lead to erroneous assessment of direct drug-induced inotropic effects due to load-dependent contractility changes (del Rio et al., 2010; Hamlin & del Rio, 2012; Suga, Sagawa, & Shoukas, 1973) . As for QTc, it is expected that each laboratory would need to assess the various dP/dt+ correction method to confirm the most effective approach. The utility of a dP/dt + correction method may be most important for compounds that induce chronotropic or pressor effects but have no or appositive inotropic effects. In contrast to the positive control drugs used in the current dataset, interpretation of dP/dt + may be challenging when only mild changes to this parameter are noted with concurrent HR or BP effects. A correction method can valuable to estimate the anticipated physiological change in dP/dt+ from the observed changes in HR and BP. Chronotropic and pressor effects are frequent in drug development and the application of a correction method for dP/dt+ has minimal cost implications while reducing the risk for incorrect interpretation in the presence confounding rate and/or pressure effects.
Modeling of the inter-dependence of cardiac parameters has a long history (Starling & Visscher, 1927) and access to new technologies may provide an opportunity to access advanced computing tools that can be Table 4 . Larger symbols represent the mean ± SE within each super-interval. B) 3D cloud analysis of uncorrected dP/dt max for different atenolol doses (control (red), low (green), mid (blue), high (teal)), with their respective confidence ellipse (95%)%) over a 24 h period using 10 min data averages (n = 3). (C) 3D cloud graph of uncorrected dP/dt max and (D) corrected dP/dt max at T max (3-5 h) after atenolol treatment (control (red), low (green), mid (blue), high (teal)), with their respective confidence ellipse (95%) using 10-min averages (n = 3 animals). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) applied to data rich studies conducted in safety pharmacology. The current analysis proposes a multi-parameter correction method for dP/ dt max , a strategy that could also be considered for other species in drug safety testing, especially given the emergence of innovative cardiac contractility measurements in rodents (Tang et al., 2016 ) and large animals (Cools et al., 2014) .
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